Trials / Terminated
TerminatedNCT03132324
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety and tolerability, and the pharmacokinetic and biologic activity of INCB059872 in participants with sickle cell disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB059872 | INCB059872 tablets |
Timeline
- Start date
- 2017-04-20
- Primary completion
- 2018-10-03
- Completion
- 2018-10-03
- First posted
- 2017-04-27
- Last updated
- 2019-10-28
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03132324. Inclusion in this directory is not an endorsement.